✦ LIBER ✦

Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate

✍ Scribed by Niklas J. Mackler; Rodney L. Dunn; Beth Hellerstedt; Kathleen A. Cooney; Judith Fardig; Karin Olson; Kenneth J. Pienta; David C. Smith

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 80 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21927

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I/II study of weekly paclitaxel

A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma

✍ Anna C. Ferrari; Abraham Chachoua; Harvinder Singh; Mark Rosenthal; Samir Taneja 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

Phase II study of the oral cyclophospham

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

✍ Catherine Maulard-Durdux; Bertrand Dufour; Christophe Hennequin; Y. Chrétien; Sy 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

## BACKGROUND. Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (vp-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tum

Oral etoposide in the treatment of hormo

Oral etoposide in the treatment of hormone-refractory prostate cancer

✍ Maha H. Hussain; Kenneth J. Pienta; Bruce G. Redman; Glenn D. Cummings; Lawrence 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB 👁 2 views

5-fluorouracil and low-dose recombinant

5-fluorouracil and low-dose recombinant interferon-α-2a in patients with hormone-refractory adenocarcinoma of the prostate

✍ Shinohara, Nobuo; Demura, Takayoshi; Matsumura, Kin-ya; Toyoda, Ken-ichi; Kashiw 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 1 views

## Background: The effectiveness of a chemotherapy regimen including 5-fluorouracil (5-fu) and recombinant interferon-alpha-2a (rifn-alpha-2a) was evaluated in hormone-refractory prostate cancer patients. ## Methods: Patients received a continuous intravenous infusion of 5-fu at 600 mg/m2/day for

Results from a pilot Phase I trial of ge

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

✍ George Wilding; Patrick Soulie; Donald Trump; Ashis Das-Gupta; Eric Small 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

Phase II trial of paclitaxel, estramusti

Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma

✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t